← Previous article

8 November 2026

Trade Margin Rationalization on Anti-Cancer Medicines

Why in news

  • National Pharmaceutical Pricing Authority capped trade margins on Maximum Retail Price for 137 anti-cancer drugs.
  • The revision covers over 1,000 formulations, significantly reducing out-of-pocket costs for cancer patients.

Key terms

NPPA

Independent pharmaceutical price regulator under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.

Trade Margin Rationalization

Capping the difference between the price at which a manufacturer sells to trade and the final MRP.

Non-scheduled Drugs

Medicines not listed under National List of Essential Medicines whose prices are monitored rather than directly fixed.

DPCO 2013

Drugs (Prices Control) Order issued under Essential Commodities Act empowering government to regulate drug prices.

What is Trade Margin Rationalization (TMR)?

  • TMR is a policy mechanism to cap the price mark-ups charged by trade channels (distributors and retailers) between stockist price and MRP.
  • It is applied to non-scheduled drugs that do not fall under direct ceiling price control under Drugs (Prices Control) Order (DPCO).
  • Imposed by NPPA under powers conferred by Para 19 of the DPCO 2013 in public interest.

Key provisions of the order

  • Caps trade margins on 137 identified anti-cancer formulations based on DGHS expert committee recommendations.
  • Covers both existing marketed formulations and prospective drugs launched in the future.
  • Mandates manufacturers and trade channels to pass price reductions directly to retail consumers.

Why it matters

  • Curbing exorbitant trade mark-ups directly mitigates catastrophic out-of-pocket healthcare expenditure for critical care.
  • Strikes a balance between pharmaceutical innovation incentives and public health affordability.

Prelims facts

  • NPPA operates under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
  • Trade Margin Rationalization targets non-scheduled medicines to prevent unreasonable trade mark-ups.

Mains discussion

  • Role of Trade Margin Rationalization in addressing catastrophic health expenditures in India.
  • Evaluating the regulatory balance between drug affordability and pharmaceutical market incentives.

Source: PIB

समान विषय · पिछले पेपर

UPSC ने यह पहले भी पूछा है

ये पिछले वर्षों के प्रश्न उसी विषय पर हैं। अभ्यास के लिए खोलें।

  1. 2025 · Q2 · GS II · 10 marks

    Comment on the need of administrative tribunals as compared to the court system. Assess the impact of the recent tribunal reforms through rationalization of tribunals made in 2021.

    उत्तर देखें →

  2. 2026 · Q41 · General Studies · 2 marks

    Which of the following statements with regard to genetic medicine is/are correct? 1. Genetic medicines correct/compensate for the faulty genes responsible for disease. 2. Engineered viruses and lipid nanoparticles are used as carriers of the genetic medicine. 3. Genetic medicines alter the entire DNA sequence. Select the answer using the code given below:

    उत्तर देखें →

← All Prelims + Mains notes for 8 November 2026

PDF
Daily news · PIB · quiz — Free